January 10, 2017 / 11:10 AM / 10 months ago

BRIEF-Valeant Pharmaceuticals announces results of second Phase 3 study for psoriasis treatment

Jan 10 (Reuters) - Valeant Pharmaceuticals International Inc

* Valeant Pharmaceuticals announces results of second phase 3 study for psoriasis treatment IDP-118

* Valeant Pharmaceuticals - IDP-118 showed statistical significance to vehicle with a treatment success rate at 8 weeks of 35.76% to 6.98%

* Valeant-Announced positive results from 2nd confirmatory pivotal phase 3, multicenter double-blind, clinical study to assess safety, efficacy of IDP-118 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below